'Unique and revolutionary'

IMAGE: Concept of the LPI building on the site of the University Hospital Jena.
view more

Credit: Woerner, Traxler, Richter Architects

In its evaluation, the WR praised the unique photonic approach, which could lead to a global improvement in diagnostics and treatment, especially of multi-resistant pathogens. The Leibniz Institute of Photonic Technology Jena e.V. (Leibniz IPHT), the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (Leibniz HKI), Jena University Hospital, and the Friedrich Schiller University of Jena under the auspices of the Leibniz Association jointly applied for the LPI.

Unique, brilliant, revolutionary, and groundbreaking - these were the words the German Council of Science and Humanities (WR) used to describe the "Leibniz Center for Photonics in Infection Research" (LPI) initiative in Jena. LPI is one of eleven project ideas for comprehenisve research infrastructure reviewed and comparatively assessed by the WR upon request of the Federal Ministry of Education and Research (BMBF). The evaluation process served as the BMBF's basis for the decision on admission into the National Roadmap, the federal program for large-scale research projects in the coming legislature period.

The combination of photonic methods and infection research leads to diagnostic approaches and targeted therapeutic methods at LPI that are directly transferable to applications and industrial production. The goal in particular is the merger of diagnostics and therapeutics - so called theragnostics. According to the WR, LPI is in a position to "revolutionize pathogen diagnostics on the global scale" and has "enormous potential in the development of novel technologies, new sensors, measurement techniques, and new lead structures."

Matthias Kleiner, president of the Leibniz Association, sees the particular charm of this project in its strong focus on application: "In Germany, LPI bridges the existing gaps in the translation of research results and drastically reduces the time to market introduction. It takes on average fourteen years for scientific results to benefit patients in the form of medical products. The reduction of this timeframe with LPI will be a major advancement."

This joint research project will commence in a new building on the Jena University Hospital campus. "This will allow us to take real patient samples under highly standardized conditions, analyze them, and work with them," said Michael Bauer, director of the Department of Anaesthesiology and Intensive Care at Jena University Hospital.

According to the WR, solutions in the targeted problem areas are of "enormous social importance." An economically positive effect can be exected for Germany as well.

Open User Platform for Fast Translation

In opinion of the WR, LPI serves a very broad user circle in science with this cross-disciplinary approach. There is also a very large economic interest to this approach. As a platform that is generally open to all users, the Leibniz Center oversees access via a peer review process that evaluates the scientific excellence of the suggested projects.

According to the assessment of the WR, LPI's unique merger of photonics and infectiology helps Germany gain significant international visibility and appeal as a center for research. In particular, LPI promotes young research scientists through the "Medical Photonics" master's program and other doctoral programs. LPI is also an attractive environment for established research scientists and clinical personnel. For Thuringia and the metropolitan region of Central Germany, infrastructure measures could mean significant developmental growth.

Establishing Ties to Renowned Collaborative Networks in Jena

The fundamental idea behind LPI is the maximum bundling of knowledge, experience, and expertise from different disciplines: at the center, the cross-disciplinary competences of the Leibniz Association and the know-how that has been available in Jena for years in the fields of photonics and infectiology merge. Concretely speaking, LPI combines under one roof the research approaches of the Leibniz research alliances "Leibniz Health Technologies" and "Infections21" with those of the InfectoGnostics research campus in Jena, a public-private partnership that has already been able to introduce products onto the market successfully for infection diagnosctics. The experience gained as part of "InfectControl2020" also plays a role. This is a federal BMBF project coordinated in Jena for all the eastern German states.

Jürgen Popp, speaker of Leibniz Health Technologies and scientific director of Leibniz IPHT, sees this cooperative approach as a unique feature of Jena: "The basis for this nationally significant project is the extraordinarily close and positive collaboration between the university, the hospital, and two Leibniz institutes, which is the defining characteristics for research in this city on the Saale River."

LPI will be implemented in three phases: After the preparatory phase (2016-2018) , which is currently running, the implementation phase (2019-2023) will begin, followed by a final operational phase on use and stabilization (2024-2033). A final decision and the publication of the National Roadmap by the BMBF can be expected at the beginning of 2018.

###

Leibniz Health Technologies is a research alliance of the Leibniz Association. Fourteen member institutes work in this alliance on concrete technological solutions to pressing medical issues; they all follow the goal together of improving medical care for patients. The cross-disciplinary approach allows the merger of prevention, diagnostics, and treatment to increase the quality of life.

The Leibniz research alliance combines competencies from very different scientific fields: from photonics and medicine to microelectronics and materials research to economic research and applied mathematics. This leads to the origination of commercially viable health technologies developed along a chain of innovation involving industry, hospitals, insurance companies, and politics. Simultaneously, Leibniz Health Technologies researches the social and economic results of new medical technologies to optimize their utilization for the user and create wide social acceptance for new technologies.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.